Magnolol
CAS 528-43-8
Magnolol (CAS 528-43-8) is a pharmaceutical compound with 7 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 51744.83568965518 nM | 58 | - |
| - | MIC | 28.903225806451612 ug.mL-1 | 31 | - |
| - | Potency | 26857.488235294117 nM | 28 | - |
| - | EC50 | 25178.909090909092 nM | 10 | - |
| - | MIC | 277666.6666666667 nM | 6 | - |
| - | IC50 | 13.680000000000001 ug.mL-1 | 5 | - |
| - | Ki | 2010 nM | 3 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| K 2P 1.1 KCNK1 |
Inhibition | 5.210000038146973 pIC50 | 37836658 |
| K Ca 1.1 KCNMA1 |
Activator | 6.0 pEC50 | 11809993 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Magnolol used for in pharmaceutical contexts?
Magnolol (CAS 528-43-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Magnolol?
No adverse-event association or SIDER side-effect rows are rendered for Magnolol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Magnolol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Magnolol with EU status "permitted".
What clinical phase is Magnolol in?
No phase 1-4 clinical development badge is rendered for Magnolol because the matched compound identifier rows do not contain a max-phase value.